VP of Regeneron Pharmaceuticals, Christopher Fenimore, disclosed the sale of 1,930 shares of company stock at $844.30 per share between December 21 and December 22, for a total transaction amount of $1,629,502.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on REGN:
- Regeneron price target raised to $1,125 from $1,050 at Oppenheimer
- Regeneron’s treatment of Hemophilia B granted FDA orphan designation
- Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
- Regeneron to host conference call
- Regeneron price target raised by $27 at Morgan Stanley, here’s why